BioCentury | Oct 5, 2009
Emerging Company Profile

Quantum Immunologics: Going to School

...Quantum Immunologics Inc. Tampa, Fla. Technology: Autologous dendritic cell immunotherapy containing oncofetal antigen/immature laminin receptor protein (OFA/iLRP) Disease focus: Cancer Clinical...
BioCentury | Oct 5, 2009
Emerging Company Profile

Quantum Immunologics: Going to School

...the antigen it uses to target the cancer cells, a cell surface receptor known as oncofetal antigen/immature laminin receptor protein (OFA/iLRP)...
...taken from the patient and processed at an external facility to isolate monocyte-derived dendritic cells. OFA/iLRP...
...antigen to the immune system, which activates T lymphocytes to target the cancer cells expressing OFA/iLRP...
Items per page:
1 - 2 of 2